BACKGROUND: Retention of children in HIV care is essential for prevention of disease progression and mortality. METHODS: Retrospective cohort of children (aged 0 to <15 years) initiating antiretroviral treatment (ART) at health facilities in Kenya, Mozambique, Rwanda, and Tanzania, from January 2005 to June 2011. Retention was defined as the proportion of children known to be alive and attending care at their initiation facility; lost to follow-up (LTF) was defined as no clinic visit for more than 6 months. Cumulative incidence of ascertained survival and retention after ART initiation was estimated through 24 months using Kaplan-Meier methods. Factors associated with LTF and death were assessed using Cox proportional hazard modeling. RESULTS: A total of 17,712 children initiated ART at 192 facilities: median age was 4.6 years [interquartile ratio (IQR), 1.9-8.3], median CD4 percent was 15% (IQR, 10-20) for children younger than 5 years and 265 cells per microliter (IQR, 111-461) for children aged 5 years or older. At 12 and 24 months, 80% and 72% of children were retained with 16% and 22% LTF and 5% and 7% known deaths, respectively. Retention ranged from 71% to 95% at 12 months and from 62% to 93% at 24 months across countries, respectively, and was lowest for children younger than 1 year (51% at 24 months). LTF and death were highest in children younger than 1 year and children with advanced disease. CONCLUSIONS: Retention was lowest in young children and differed across country programs. Young children and those with advanced disease are at highest risk for LTF and death. Further evaluation of patient- and program-level factors is needed to improve health outcomes.
BACKGROUND: Retention of children in HIV care is essential for prevention of disease progression and mortality. METHODS: Retrospective cohort of children (aged 0 to <15 years) initiating antiretroviral treatment (ART) at health facilities in Kenya, Mozambique, Rwanda, and Tanzania, from January 2005 to June 2011. Retention was defined as the proportion of children known to be alive and attending care at their initiation facility; lost to follow-up (LTF) was defined as no clinic visit for more than 6 months. Cumulative incidence of ascertained survival and retention after ART initiation was estimated through 24 months using Kaplan-Meier methods. Factors associated with LTF and death were assessed using Cox proportional hazard modeling. RESULTS: A total of 17,712 children initiated ART at 192 facilities: median age was 4.6 years [interquartile ratio (IQR), 1.9-8.3], median CD4 percent was 15% (IQR, 10-20) for children younger than 5 years and 265 cells per microliter (IQR, 111-461) for children aged 5 years or older. At 12 and 24 months, 80% and 72% of children were retained with 16% and 22% LTF and 5% and 7% known deaths, respectively. Retention ranged from 71% to 95% at 12 months and from 62% to 93% at 24 months across countries, respectively, and was lowest for children younger than 1 year (51% at 24 months). LTF and death were highest in children younger than 1 year and children with advanced disease. CONCLUSIONS: Retention was lowest in young children and differed across country programs. Young children and those with advanced disease are at highest risk for LTF and death. Further evaluation of patient- and program-level factors is needed to improve health outcomes.
Authors: Delphine Sauvageot; Myrto Schaefer; David Olson; Mar Pujades-Rodriguez; Daniel P O'Brien Journal: Pediatrics Date: 2010-04-12 Impact factor: 7.124
Authors: Michael L Rich; Ann C Miller; Peter Niyigena; Molly F Franke; Jean Bosco Niyonzima; Adrienne Socci; Peter C Drobac; Massudi Hakizamungu; Alishya Mayfield; Robert Ruhayisha; Henry Epino; Sara Stulac; Corrado Cancedda; Adolph Karamaga; Saleh Niyonzima; Chase Yarbrough; Julia Fleming; Cheryl Amoroso; Joia Mukherjee; Megan Murray; Paul Farmer; Agnes Binagwaho Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: N K M van Kooten Niekerk; M M Knies; J Howard; H Rabie; M Zeier; A van Rensburg; N Frans; H S Schaaf; G Fatti; F Little; M F Cotton Journal: J Trop Pediatr Date: 2005-06-09 Impact factor: 1.165
Authors: Mary-Ann Davies; Olivia Keiser; Karl Technau; Brian Eley; Helena Rabie; Gilles van Cutsem; Janet Giddy; Robin Wood; Andrew Boulle; Matthias Egger; Harry Moultrie Journal: S Afr Med J Date: 2009-10
Authors: Dalton C Wamalwa; Elizabeth M Obimbo; Carey Farquhar; Barbra A Richardson; Dorothy A Mbori-Ngacha; Irene Inwani; Sara Benki-Nugent; Grace John-Stewart Journal: BMC Pediatr Date: 2010-05-18 Impact factor: 2.125
Authors: Anirban Chatterjee; Sangeeta Tripathi; Robert Gass; Ndapewa Hamunime; Sok Panha; Charles Kiyaga; Abdoulaye Wade; Matthew Barnhart; Chewe Luo; Rene Ekpini Journal: BMC Public Health Date: 2011-07-13 Impact factor: 3.295
Authors: Margaret L McNairy; Matthew R Lamb; Elaine J Abrams; Batya Elul; Ruben Sahabo; Mark P Hawken; Antonio Mussa; Ayele Zwede; Jessica Justman; Wafaa M El-Sadr Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.731
Authors: Mireille Porter; Mary-Ann Davies; Muntanga K Mapani; Helena Rabie; Sam Phiri; James Nuttall; Lee Fairlie; Karl-Günter Technau; Kathryn Stinson; Robin Wood; Maureen Wellington; Andreas D Haas; Janet Giddy; Frank Tanser; Brian Eley Journal: J Acquir Immune Defic Syndr Date: 2015-08-15 Impact factor: 3.731
Authors: Andrew F Auld; Charity Alfredo; Eugenia Macassa; Kebba Jobarteh; Ray W Shiraishi; Emilia D Rivadeneira; James Houston; Thomas J Spira; Tedd V Ellerbrock; Paula Vaz Journal: Pediatr Infect Dis J Date: 2015-08 Impact factor: 2.129